Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-09-10
2002-10-01
Owens, Amelia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S459000, C514S422000, C514S397000, C514S359000, C514S326000, C514S231500, C549S416000, C549S417000, C549S419000, C544S149000, C548S266200, C548S311100, C548S255000, C548S517000, C546S207000
Reexamination Certificate
active
06458830
ABSTRACT:
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a U.S. National Phase application under 35 U.S.C. § 371 of PCT Application No. PCT/GB00/00974, filed Mar. 16, 2000, which claims priority under 35 U.S.C. § 119 from GB Application No. 9906480.0, filed Mar. 19, 1999 and GB Application No. 9924616.7 filed Oct. 18, 1999.
This invention relates to a class of tetrahydropyran compounds which are useful as tachykinin antagonists. More particularly, the compounds of the invention are useful as neurokinin 1(NK-1) receptor antagonists.
The present invention provides compounds of the formula (I):
wherein
R
1
is hydrogen, halogen, C
1-6
alkyl, C
1-6
alkoxy, fluoroC
1-6
alkyl, fluoroC
1-6
alkoxy, C
3-7
cycloalkyl, C
3-7
cycloalkylC
1-4
alkyl, NO
2
, CN, SR
a
, SOR
a
, SO
2
R
a
, CO
2
R
a
, CONR
a
R
b
, C
2-6
alkenyl, C
2-6
alkynyl or C
1-4
alkyl substituted by C
1-4
alkoxy, wherein R
a
and R
b
each independently represent hydrogen or C
1-4
alkyl;
R
2
is hydrogen, halogen, C
1-6
alkyl, fluoroC
1-6
alkyl or C
1-6
alkoxy substituted by C
1-4
alkoxy;
R
3
is hydrogen, halogen or fluoroC
1-6
alkyl;
R
4
is hydrogen, halogen, C
1-6
alkyl, C
1-6
alkoxy, fluoroC
1-6
alkyl, fluoroC
1-6
alkoxy, hydroxy, NO
2
, CN, SR
a
, SOR
a
, SO
2
R
a
, CO
2
R
a
, CONR
a
R
b
, C
2-6
alkenyl, C
2-6
alkynyl or C
1-4
alkyl substituted by C
1-4
alkoxy, wherein R
a
and R
b
are as previously defined;
R
5
is hydrogen, halogen, C
1-6
alkyl, fluoroC
1-6
alkyl or C
1-6
alkoxy substituted by C
1-4
alkoxy;
R
6
represents hydrogen or a C
1-4
alkyl group optionally substituted by a hydroxy group;
R
7
represents halogen, hydroxy, C
2-4
alkenyl, C
2-4
alkynyl, N
3
, —NR
11
R
12
, —NR
a
COR
b
, —OSO
2
R
a
, —(CH
2
)
p
NR
a
(CH
2
)
q
COOR
b
, COR
a
, COOR
a
, —N═C═O, or a five membered or six membered nitrogen-containing heteroaromatic ring optionally containing 1, 2 or 3 additional heteroatoms selected from N, O and S which heteroaromatic ring is optionally substituted at any substitutable position by a substituent selected from ═O, ═S, halogen, hydroxy, —SH, COR
a
, CO
2
R
a
, —ZNR
11
R
12
, C
1-4
alkyl, hydroxyC
1-4
alkyl, fluoroC
1-4
alkyl, chloroC
1-4
alkyl, C
1-4
alkoxy, fluoroC
1-4
alkoxy or C
1-4
alkoxy substituted by a C
1-4
alkoxy or hydroxyl group, and wherein said C
2-4
alkenyl and C
2-4
alkynyl groups are optionally substituted by a substituent selected from halogen, hydroxy, N
3
, —NR
11
R
12
, —NR
a
COR
b
, —OSO
2
R
a
, —(CH
2
)
p
NR
a
(CH
2
)
q
COOR
b
, COR
a
or COOR
a
;
R
8
represents hydrogen, C
1-6
alkyl, fluoroC
1-6
alkyl, hydroxy, C
1-6
alkoxy or hydroxyC
1-6
alkyl;
R
9
and R
10
each independently represent hydrogen, halogen, C
1-6
alkyl, CH
2
OR
c
, oxo, CO
2
R
a
or CONR
a
R
b
where R
a
and R
b
are as previously defined and R
c
represents hydrogen, C
1-6
alkyl or phenyl;
R
11
is hydrogen, C
1-4
alkyl, C
3-7
cycloalkyl, C
3-7
cycloalkylC
1-4
alkyl, C
2-4
alkyl substituted by a C
1-4
alkoxy or hydroxyl group, or R
11
is a five membered or six membered nitrogen-containing heteroaromatic ring as previously defined;
R
12
is hydrogen or C
1-4
alkyl, C
3-7
cycloalkyl, C
3-7
cycloalkylC
1-4
alkyl, or C
2-4
alkyl substituted by a C
1-4
alkoxy or hydroxyl group;
or R
11
, R
12
and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy, COR
e
, CO
2
R
e
, C
1-4
alkyl optionally substituted by a C
1-4
alkoxy or hydroxyl group, or C
1-4
alkoxy optionally substituted by a C
1-4
alkoxy or hydroxyl group, or a five membered or six membered nitrogen-containing heteroaromatic ring as previously defined, or said heteroaliphatic ring is substituted by a spiro-fused lactone ring, and said heteroaliphatic ring optionally containing a double bond, which heteroaliphatic ring may optionally contain an oxygen or sulphur ring atom, a group S(O) or S(O)
2
or a second nitrogen atom which will be part of a NH or NR
d
moiety, where R
d
is C
1-4
alkyl optionally substituted by hydroxy or C
1-4
alkoxy, and where R
e
is hydrogen, C
1-4
alkyl or benzyl;
or R
11
, R
12
and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms;
or R
11
, R
12
and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms to which is fused a benzene ring or a five membered or six membered nitrogen-containing heteroaromatic ring ring optionally containing 1, 2 or 3 additional heteroatoms selected from N, O and S;
Z represents a bond, C
1-6
alkylene or C
3-6
cycloalkylene;
n is zero, 1 or 2;
p is 1 or 2; and
q is 1 or 2;
and pharmaceutically acceptable salts thereof.
A preferred class of compounds of formula (I) is that wherein:
R
7
represents halogen, hydroxy, C
2-4
alkenyl, N
3
, —NR
11
R
12
, —NR
a
COR
b
, —OSO
2
R
a
, —(CH
2
)
p
NR
a
(CH
2
)
q
COOR
b
, COR
a
, COOR
a
, or a five membered or six membered nitrogen-containing heteroaromatic ring optionally containing 1, 2 or 3 additional heteroatoms selected from N, O and S which heteroaromatic ring is optionally substituted at any substitutable position by a substituent selected from ═O, ═S, halogen, hydroxy, —SH, COR
a
, CO
2
R
a
, —ZNR
11
R
12
, C
1-4
alkyl, hydroxyC
1-4
alkyl, fluoroC
1-4
alkyl, C
1-4
alkoxy, fluoroC
1-4
alkoxy or C
1-4
alkoxy substituted by a C
1-4
alkoxy or hydroxyl group.
Another preferred class of compounds of formula (I) is that wherein:
R
7
represents halogen, hydroxy, C
2-4
alkenyl, N
3
, —NR
11
R
12
, —NR
a
COR
b
, —OSO
2
R
a
, —(CH
2
)
p
NR
a
(CH
2
)
q
COOR
b
or a five membered or six membered nitrogen-containing heteroaromatic ring optionally containing 1, 2 or 3 additional heteroatoms selected from N, O and S which heteroaromatic ring is optionally substituted at any substitutable position by a substituent selected from ═O, ═S, halogen, hydroxy, —SH, COR
a
, CO
2
R
a
, —ZNR
11
R
12
, C
1-4
alkyl, hydroxyC
1-4
alkyl, fluoroC
1-4
alkyl, C
1-4
alkoxy, fluoroC
1-4
alkoxy or C
1-4
alkoxy substituted by a C
1-4
alkoxy or hydroxyl group;
R
11
is hydrogen or C
1-4
alkyl, C
3-7
cycloalkyl, C
3-7
cycloalkylC
1-4
alkyl, or C
2-4
alkyl substituted by a C
1-4
alkoxy or hydroxyl group;
R
12
is hydrogen or C
1-4
alkyl, C
3-7
cycloalkyl, C
3-7
cycloalkylC
1-4
alkyl, or C
2-4
alkyl substituted by a C
1-4
alkoxy or hydroxyl group;
or R
11
, R
12
and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy, COR
a
, CO
2
R
a
or C
1-4
alkoxy optionally substituted by a C
1-4
alkoxy or hydroxyl group, and said ring optionally containing a double bond, which ring may optionally contain an oxygen or sulphur ring atom, a group S(O) or S(O)
2
or a second nitrogen atom which will be part of a NH or NR
d
moiety where R
d
is C
1-4
alkyl optionally substituted by hydroxy or C
1-4
alkoxy;
or R
11
, R
12
and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms;
or a pharmaceutically acceptable salt thereof.
A further preferred class of compounds of formula (I) is that wherein R
1
is hydrogen, C
1-4
alkyl, C
1-4
alkoxy, halogen or CF
3
.
Another preferred class of compounds of formula (I) is that wherein R
2
is hydrogen, C
1-4
alkyl, C
1-4
alkoxy, halogen or CF
3
.
Also preferred is the class of compounds of formula (I) wherein R
3
is hydrogen, fluorine, chlorine or CF
3
.
A particularly preferred class of compounds of formula (I) is that wherein R
1
is fluorine, chlorine or CF
3
.
Another particularly preferred class of compounds of formula (I) is that wherein R
2
is hydrogen, fluorine, chlorine or CF
3
.
Also particularly preferred is the class of compounds of formula (I) wherein R
3
is hydrogen, fluorine, chlorine or CF
3
.
Preferably R
1
and R
2
are in the 3 and 5 positions of the phenyl ring.
More preferably R
1
is 3-fluoro or 3-CF
3
.
More preferably R
2
is 5-fluoro or 5-CF
3
.
More preferably R
3
is hydrogen.
Most preferably R
1
is 3-F or 3-CF
3
, R
2
is
Owen Simon Neil
Seward Eileen Mary
Swain Christopher John
Williams Brian John
Merck Sharp & Dohme Ltd.
Owens Amelia
Thies J. Eric
Winokur Mel
LandOfFree
Tetrahydropyran derivatives and their use as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydropyran derivatives and their use as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydropyran derivatives and their use as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2998481